Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study

BackgroundDyslipidemia, a key modifiable risk factor for cardiovascular diseases, is managed using lipid-lowering therapies. Medication adherence for dyslipidemia treatment is poor across the globe, impacting treatment effectiveness. This highlights the need for scalable strategies, such as mobile a...

Full description

Saved in:
Bibliographic Details
Main Authors: Chatlert Pongchaiyakul, Stefan Driessen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Digital Health
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fdgth.2025.1502990/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849425556419903488
author Chatlert Pongchaiyakul
Stefan Driessen
author_facet Chatlert Pongchaiyakul
Stefan Driessen
author_sort Chatlert Pongchaiyakul
collection DOAJ
description BackgroundDyslipidemia, a key modifiable risk factor for cardiovascular diseases, is managed using lipid-lowering therapies. Medication adherence for dyslipidemia treatment is poor across the globe, impacting treatment effectiveness. This highlights the need for scalable strategies, such as mobile app-based behavioral interventions, to enhance adherence to lipid-lowering therapies.ObjectiveThe study assesses the impact of “My A:Care” and “My A:Care Smart Coach” mobile interventions on adherence to dyslipidemia treatment.MethodsThis proof-of-concept, open-label, single-center study randomized 150 patients with suboptimal adherence to dyslipidemia treatment into three groups (1:1:1): My A:Care, My A:Care Smart Coach (intervention), and a no-app control group. Participants were monitored over 12 weeks. The primary objective was to assess changes in medication adherence, with secondary outcomes including changes in lipid parameters and beliefs about lipid-lowering medications. The study also explored the association between adherence and app engagement.ResultsAt week 12, the Medication Adherence Report with Visual Analog Scale (MARS-5VA) Part 1 scores were modestly, but significantly lower in the control group compared to the intervention groups: Mean (SD); No-App: −0.3 (0.9), Smart Coach: 0.0 (0.7) [p = 0.035], My A:Care-All: 0.0 (0.7) [p = 0.056]. Compared to the control, the intervention groups also showed greater improvements in non-HDL-C levels [% change (SE): My A:Care-All: −5.5% (3.2), Smart Coach: −4.3% (3.7), No-App: −1.8% (3.7)], along with favorable trends in TC, LDL-C, and HDL-C.ConclusionThis proof-of-concept study suggests that the My A:Care and Smart Coach apps may positively impact adherence to lipid-lowering therapy in patients with dyslipidemia. The positive adherence outcomes and potential benefits in lipid control indicate promising early signals that warrant further investigation in larger, confirmatory studies. Clinical Trial RegistrationNCT05370703.
format Article
id doaj-art-7ca080f81ba1439eb0a256c3aa522fe8
institution Kabale University
issn 2673-253X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Digital Health
spelling doaj-art-7ca080f81ba1439eb0a256c3aa522fe82025-08-20T03:29:44ZengFrontiers Media S.A.Frontiers in Digital Health2673-253X2025-07-01710.3389/fdgth.2025.15029901502990Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical studyChatlert Pongchaiyakul0Stefan Driessen1Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandEstablished Pharmaceuticals Division, Global Biometrics, Abbott Healthcare Products B.V, Weesp, NetherlandsBackgroundDyslipidemia, a key modifiable risk factor for cardiovascular diseases, is managed using lipid-lowering therapies. Medication adherence for dyslipidemia treatment is poor across the globe, impacting treatment effectiveness. This highlights the need for scalable strategies, such as mobile app-based behavioral interventions, to enhance adherence to lipid-lowering therapies.ObjectiveThe study assesses the impact of “My A:Care” and “My A:Care Smart Coach” mobile interventions on adherence to dyslipidemia treatment.MethodsThis proof-of-concept, open-label, single-center study randomized 150 patients with suboptimal adherence to dyslipidemia treatment into three groups (1:1:1): My A:Care, My A:Care Smart Coach (intervention), and a no-app control group. Participants were monitored over 12 weeks. The primary objective was to assess changes in medication adherence, with secondary outcomes including changes in lipid parameters and beliefs about lipid-lowering medications. The study also explored the association between adherence and app engagement.ResultsAt week 12, the Medication Adherence Report with Visual Analog Scale (MARS-5VA) Part 1 scores were modestly, but significantly lower in the control group compared to the intervention groups: Mean (SD); No-App: −0.3 (0.9), Smart Coach: 0.0 (0.7) [p = 0.035], My A:Care-All: 0.0 (0.7) [p = 0.056]. Compared to the control, the intervention groups also showed greater improvements in non-HDL-C levels [% change (SE): My A:Care-All: −5.5% (3.2), Smart Coach: −4.3% (3.7), No-App: −1.8% (3.7)], along with favorable trends in TC, LDL-C, and HDL-C.ConclusionThis proof-of-concept study suggests that the My A:Care and Smart Coach apps may positively impact adherence to lipid-lowering therapy in patients with dyslipidemia. The positive adherence outcomes and potential benefits in lipid control indicate promising early signals that warrant further investigation in larger, confirmatory studies. Clinical Trial RegistrationNCT05370703.https://www.frontiersin.org/articles/10.3389/fdgth.2025.1502990/fulldyslipidemiamedication adherencemedication non-adherencemobile applicationsbehavioral interventionslipid-lowering therapies
spellingShingle Chatlert Pongchaiyakul
Stefan Driessen
Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
Frontiers in Digital Health
dyslipidemia
medication adherence
medication non-adherence
mobile applications
behavioral interventions
lipid-lowering therapies
title Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
title_full Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
title_fullStr Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
title_full_unstemmed Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
title_short Evaluating the effect of mobile applications “My A:Care” and “Smart Coach” on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study
title_sort evaluating the effect of mobile applications my a care and smart coach on adherence to lipid lowering treatment in patients with dyslipidemia a prospective randomized open label clinical study
topic dyslipidemia
medication adherence
medication non-adherence
mobile applications
behavioral interventions
lipid-lowering therapies
url https://www.frontiersin.org/articles/10.3389/fdgth.2025.1502990/full
work_keys_str_mv AT chatlertpongchaiyakul evaluatingtheeffectofmobileapplicationsmyacareandsmartcoachonadherencetolipidloweringtreatmentinpatientswithdyslipidemiaaprospectiverandomizedopenlabelclinicalstudy
AT stefandriessen evaluatingtheeffectofmobileapplicationsmyacareandsmartcoachonadherencetolipidloweringtreatmentinpatientswithdyslipidemiaaprospectiverandomizedopenlabelclinicalstudy